APO Research
Talk to an analyst

APO RESEARCH · REPORT

Generic and Biosimilar Pharmaceuticals

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Generic and Biosimilar Pharmaceuticals Industry Growth and Trends Forecast to 2032

31 December 2025113 pages

Choose your research edition.

Industry ResearchGeneric and Biosimilar Pharmaceuticals Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Generic and Biosimilar Pharmaceuticals Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Generic and Biosimilar Pharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Generic and Biosimilar Pharmaceuticals Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Generic and Biosimilar Pharmaceuticals Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

According to APO Research, the global Generic and Biosimilar Pharmaceuticals market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Generic and Biosimilar Pharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Generic and Biosimilar Pharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Generic and Biosimilar Pharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Generic and Biosimilar Pharmaceuticals market include Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Amgen, AbbVie and Sanofi-Aventis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Generic and Biosimilar Pharmaceuticals market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Generic and Biosimilar Pharmaceuticals market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Generic and Biosimilar Pharmaceuticals market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Generic and Biosimilar Pharmaceuticals.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Generic and Biosimilar Pharmaceuticals market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Generic and Biosimilar Pharmaceuticals Market by Company

Johnson & Johnson

Novartis

Merck

Roche

Eli Lilly

Pfizer

Amgen

AbbVie

Sanofi-Aventis

Novo Nordisk

Innovent

Gelgen

Ganlee

Dong Bao

CP Guojian

Changchun High Tech

Biotech

3sbio

Generic and Biosimilar Pharmaceuticals Segment by Type

Erythropoietin

Monoclonal Antibodies

Interferon

Insulin

Vaccines

Other

Generic and Biosimilar Pharmaceuticals Segment by Application

Tumor

Hemophilia

Cardiovascular

Diabetes

Other

Generic and Biosimilar Pharmaceuticals Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic and Biosimilar Pharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Generic and Biosimilar Pharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic and Biosimilar Pharmaceuticals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Generic and Biosimilar Pharmaceuticals companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Generic and Biosimilar Pharmaceuticals Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Generic and Biosimilar Pharmaceuticals Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Generic and Biosimilar Pharmaceuticals Market Share by Region (2021-2026) Table 4. Global Generic and Biosimilar Pharmaceuticals Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Generic and Biosimilar Pharmaceuticals Market Share by Region (2027-2032) Table 6. Global Generic and Biosimilar Pharmaceuticals Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Generic and Biosimilar Pharmaceuticals Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Generic and Biosimilar Pharmaceuticals Market Size Share by Type (2021-2026) Table 9. Global Generic and Biosimilar Pharmaceuticals Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Generic and Biosimilar Pharmaceuticals Market Size Share Forecasted by Type (2027-2032) Table 11. North America Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Generic and Biosimilar Pharmaceuticals Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Generic and Biosimilar Pharmaceuticals Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Generic and Biosimilar Pharmaceuticals Market Size Share by Application (2021-2026) Table 24. Global Generic and Biosimilar Pharmaceuticals Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Generic and Biosimilar Pharmaceuticals Market Size Share Forecasted by Application (2027-2032) Table 26. North America Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Generic and Biosimilar Pharmaceuticals Industry Trends Table 37. Generic and Biosimilar Pharmaceuticals Industry Drivers Table 38. Generic and Biosimilar Pharmaceuticals Industry Opportunities and Challenges Table 39. Generic and Biosimilar Pharmaceuticals Industry Restraints Table 40. Global Generic and Biosimilar Pharmaceuticals Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Generic and Biosimilar Pharmaceuticals Revenue Market Share by Company (2021-2026) Table 42. Global Generic and Biosimilar Pharmaceuticals Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Generic and Biosimilar Pharmaceuticals Key Company Headquarters & Area Served Table 44. Global Generic and Biosimilar Pharmaceuticals Company, Product Type & Application Table 45. Global Generic and Biosimilar Pharmaceuticals Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Generic and Biosimilar Pharmaceuticals by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Johnson & Johnson Company Information Table 49. Johnson & Johnson Business Overview Table 50. Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Johnson & Johnson Generic and Biosimilar Pharmaceuticals Product Portfolio Table 52. Johnson & Johnson Recent Development Table 53. Novartis Company Information Table 54. Novartis Business Overview Table 55. Novartis Generic and Biosimilar Pharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Novartis Generic and Biosimilar Pharmaceuticals Product Portfolio Table 57. Novartis Recent Development Table 58. Merck Company Information Table 59. Merck Business Overview Table 60. Merck Generic and Biosimilar Pharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Merck Generic and Biosimilar Pharmaceuticals Product Portfolio Table 62. Merck Recent Development Table 63. Roche Company Information Table 64. Roche Business Overview Table 65. Roche Generic and Biosimilar Pharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Roche Generic and Biosimilar Pharmaceuticals Product Portfolio Table 67. Roche Recent Development Table 68. Eli Lilly Company Information Table 69. Eli Lilly Business Overview Table 70. Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Eli Lilly Generic and Biosimilar Pharmaceuticals Product Portfolio Table 72. Eli Lilly Recent Development Table 73. Pfizer Company Information Table 74. Pfizer Business Overview Table 75. Pfizer Generic and Biosimilar Pharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Pfizer Generic and Biosimilar Pharmaceuticals Product Portfolio Table 77. Pfizer Recent Development Table 78. Amgen Company Information Table 79. Amgen Business Overview Table 80. Amgen Generic and Biosimilar Pharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Amgen Generic and Biosimilar Pharmaceuticals Product Portfolio Table 82. Amgen Recent Development Table 83. AbbVie Company Information Table 84. AbbVie Business Overview Table 85. AbbVie Generic and Biosimilar Pharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. AbbVie Generic and Biosimilar Pharmaceuticals Product Portfolio Table 87. AbbVie Recent Development Table 88. Sanofi-Aventis Company Information Table 89. Sanofi-Aventis Business Overview Table 90. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Product Portfolio Table 92. Sanofi-Aventis Recent Development Table 93. Novo Nordisk Company Information Table 94. Novo Nordisk Business Overview Table 95. Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Novo Nordisk Generic and Biosimilar Pharmaceuticals Product Portfolio Table 97. Novo Nordisk Recent Development Table 98. Innovent Company Information Table 99. Innovent Business Overview Table 100. Innovent Generic and Biosimilar Pharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Innovent Generic and Biosimilar Pharmaceuticals Product Portfolio Table 102. Innovent Recent Development Table 103. Gelgen Company Information Table 104. Gelgen Business Overview Table 105. Gelgen Generic and Biosimilar Pharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Gelgen Generic and Biosimilar Pharmaceuticals Product Portfolio Table 107. Gelgen Recent Development Table 108. Ganlee Company Information Table 109. Ganlee Business Overview Table 110. Ganlee Generic and Biosimilar Pharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Ganlee Generic and Biosimilar Pharmaceuticals Product Portfolio Table 112. Ganlee Recent Development Table 113. Dong Bao Company Information Table 114. Dong Bao Business Overview Table 115. Dong Bao Generic and Biosimilar Pharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Dong Bao Generic and Biosimilar Pharmaceuticals Product Portfolio Table 117. Dong Bao Recent Development Table 118. CP Guojian Company Information Table 119. CP Guojian Business Overview Table 120. CP Guojian Generic and Biosimilar Pharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. CP Guojian Generic and Biosimilar Pharmaceuticals Product Portfolio Table 122. CP Guojian Recent Development Table 123. Changchun High Tech Company Information Table 124. Changchun High Tech Business Overview Table 125. Changchun High Tech Generic and Biosimilar Pharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Changchun High Tech Generic and Biosimilar Pharmaceuticals Product Portfolio Table 127. Changchun High Tech Recent Development Table 128. Biotech Company Information Table 129. Biotech Business Overview Table 130. Biotech Generic and Biosimilar Pharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Biotech Generic and Biosimilar Pharmaceuticals Product Portfolio Table 132. Biotech Recent Development Table 133. 3sbio Company Information Table 134. 3sbio Business Overview Table 135. 3sbio Generic and Biosimilar Pharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. 3sbio Generic and Biosimilar Pharmaceuticals Product Portfolio Table 137. 3sbio Recent Development Table 138. North America Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. North America Generic and Biosimilar Pharmaceuticals Market Size by Country (2021-2026) & (US$ Million) Table 140. North America Generic and Biosimilar Pharmaceuticals Market Share by Country (2021-2026) Table 141. North America Generic and Biosimilar Pharmaceuticals Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. North America Generic and Biosimilar Pharmaceuticals Market Share Forecast by Country (2027-2032) Table 143. Europe Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Europe Generic and Biosimilar Pharmaceuticals Market Size by Country (2021-2026) & (US$ Million) Table 145. Europe Generic and Biosimilar Pharmaceuticals Market Share by Country (2021-2026) Table 146. Europe Generic and Biosimilar Pharmaceuticals Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Europe Generic and Biosimilar Pharmaceuticals Market Share Forecast by Country (2027-2032) Table 148. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size by Country (2021-2026) & (US$ Million) Table 150. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Share by Country (2021-2026) Table 151. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Share Forecast by Country (2027-2032) Table 153. Latin America Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Latin America Generic and Biosimilar Pharmaceuticals Market Size by Country (2021-2026) & (US$ Million) Table 155. Latin America Generic and Biosimilar Pharmaceuticals Market Share by Country (2021-2026) Table 156. Latin America Generic and Biosimilar Pharmaceuticals Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Latin America Generic and Biosimilar Pharmaceuticals Market Share Forecast by Country (2027-2032) Table 158. Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size by Country (2021-2026) & (US$ Million) Table 160. Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Share by Country (2021-2026) Table 161. Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Share Forecast by Country (2027-2032) Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Generic and Biosimilar Pharmaceuticals Product Image Figure 3. Global Generic and Biosimilar Pharmaceuticals Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Generic and Biosimilar Pharmaceuticals Market Size (2021-2032) & (US$ Million) Figure 5. Global Generic and Biosimilar Pharmaceuticals Market Share by Region: 2025 VS 2032 Figure 6. Global Generic and Biosimilar Pharmaceuticals Market Share by Region (2021-2032) Figure 7. North America Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Erythropoietin Image Figure 13. Global Erythropoietin Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Monoclonal Antibodies Image Figure 15. Global Monoclonal Antibodies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Interferon Image Figure 17. Global Interferon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Insulin Image Figure 19. Global Insulin Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Vaccines Image Figure 21. Global Vaccines Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Other Image Figure 23. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Global Generic and Biosimilar Pharmaceuticals Market Size Overview by Type (2021-2032) & (US$ Million) Figure 25. Global Generic and Biosimilar Pharmaceuticals Market Share by Type 2025 VS 2032 Figure 26. North America Generic and Biosimilar Pharmaceuticals Market Size Share by Type (2021-2032) Figure 27. Europe Generic and Biosimilar Pharmaceuticals Market Size Share by Type (2021-2032) Figure 28. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size Share by Type (2021-2032) Figure 29. Latin America Generic and Biosimilar Pharmaceuticals Market Size Share by Type (2021-2032) Figure 30. Middle East and Africa Generic and Biosimilar Pharmaceuticals Market Size Share by Type (2021-2032) Figure 31. Tumor Image Figure 32. Global Tumor Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Hemophilia Image Figure 34. Global Hemophilia Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Cardiovascular Image Figure 36. Global Cardiovascular Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Diabetes Image Figure 38. Global Diabetes Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Other Image Figure 40. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. Global Generic and Biosimilar Pharmaceuticals Market Size Overview by Application (2021-2032) & (US$ Million) Figure 42. Global Generic and Biosimilar Pharmaceuticals Market Share by Application 2025 VS 2032 Figure 43. North America Generic and Biosimilar Pharmaceuticals Market Size Share by Application (2021-2032) Figure 44. Europe Generic and Biosimilar Pharmaceuticals Market Size Share by Application (2021-2032) Figure 45. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size Share by Application (2021-2032) Figure 46. Latin America Generic and Biosimilar Pharmaceuticals Market Size Share by Application (2021-2032) Figure 47. Middle East and Africa Generic and Biosimilar Pharmaceuticals Market Size Share by Application (2021-2032) Figure 48. Global Top 5 and 10 Generic and Biosimilar Pharmaceuticals Players Market Share by Revenue in 2025 Figure 49. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 50. North America Generic and Biosimilar Pharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. North America Generic and Biosimilar Pharmaceuticals Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. North America Generic and Biosimilar Pharmaceuticals Market Share by Country (2021-2032) Figure 53. Europe Generic and Biosimilar Pharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Generic and Biosimilar Pharmaceuticals Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Generic and Biosimilar Pharmaceuticals Market Share by Country (2021-2032) Figure 56. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Share by Country: 2021 VS 2025 VS 2032 Figure 58. Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Share by Country (2021-2032) Figure 59. Latin America Generic and Biosimilar Pharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Generic and Biosimilar Pharmaceuticals Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Generic and Biosimilar Pharmaceuticals Market Share by Country (2021-2032) Figure 62. Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 63. Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Share by Country: 2021 VS 2025 VS 2032 Figure 64. Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Share by Country (2021-2032) Figure 65. Years Considered Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Erythropoietin
  • Monoclonal Antibodies
  • Interferon
  • Insulin
  • Vaccines
  • Other
Applications
  • Tumor
  • Hemophilia
  • Cardiovascular
  • Diabetes
  • Other
Companies covered
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • Amgen
  • AbbVie
  • Sanofi-Aventis
  • Novo Nordisk
  • Innovent
  • Gelgen
  • Ganlee
  • Dong Bao
  • CP Guojian
  • Changchun High Tech
  • Biotech
  • 3sbio

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Generic and Biosimilar Pharmaceuticals Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Generic and Biosimilar Pharmaceuticals Market Size by Region (2021-2032)
  5. 1.4.1 Global Generic and Biosimilar Pharmaceuticals Market Size by Region (2021-2026)
  6. 1.4.2 Global Generic and Biosimilar Pharmaceuticals Market Size by Region (2027-2032)
  7. 1.5 Key Regions Generic and Biosimilar Pharmaceuticals Market Size (2021-2032)
  8. 1.5.1 North America Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (2021-2032)
2 Generic and Biosimilar Pharmaceuticals Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Erythropoietin
  3. 2.1.2 Monoclonal Antibodies
  4. 2.1.3 Interferon
  5. 2.1.4 Insulin
  6. 2.1.5 Vaccines
  7. 2.1.6 Other
  8. 2.2 Global Generic and Biosimilar Pharmaceuticals Market Size by Type
  9. 2.2.1 Global Generic and Biosimilar Pharmaceuticals Market Size Overview by Type (2021-2032)
  10. 2.2.2 Global Generic and Biosimilar Pharmaceuticals Historic Market Size Review by Type (2021-2026)
  11. 2.2.3 Global Generic and Biosimilar Pharmaceuticals Market Size Forecasted by Type (2027-2032)
  12. 2.3 Global Generic and Biosimilar Pharmaceuticals Market Size by Regions
  13. 2.3.1 North America Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Type (2021-2026)
  14. 2.3.2 Europe Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Type (2021-2026)
  15. 2.3.3 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Type (2021-2026)
  16. 2.3.4 South America Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Type (2021-2026)
  17. 2.3.5 Middle East and Africa Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Type (2021-2026)
3 Generic and Biosimilar Pharmaceuticals Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Tumor
  3. 3.1.2 Hemophilia
  4. 3.1.3 Cardiovascular
  5. 3.1.4 Diabetes
  6. 3.1.5 Other
  7. 3.2 Global Generic and Biosimilar Pharmaceuticals Market Size by Application
  8. 3.2.1 Global Generic and Biosimilar Pharmaceuticals Market Size Overview by Application (2021-2032)
  9. 3.2.2 Global Generic and Biosimilar Pharmaceuticals Historic Market Size Review by Application (2021-2026)
  10. 3.2.3 Global Generic and Biosimilar Pharmaceuticals Market Size Forecasted by Application (2027-2032)
  11. 3.3 Global Generic and Biosimilar Pharmaceuticals Market Size by Regions
  12. 3.3.1 North America Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Application (2021-2026)
  13. 3.3.2 Europe Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Application (2021-2026)
  14. 3.3.3 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Application (2021-2026)
  15. 3.3.4 South America Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Application (2021-2026)
  16. 3.3.5 Middle East and Africa Generic and Biosimilar Pharmaceuticals Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Generic and Biosimilar Pharmaceuticals Industry Trends
  2. 4.2 Generic and Biosimilar Pharmaceuticals Industry Drivers
  3. 4.3 Generic and Biosimilar Pharmaceuticals Industry Opportunities and Challenges
  4. 4.4 Generic and Biosimilar Pharmaceuticals Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Generic and Biosimilar Pharmaceuticals Revenue (2021-2026)
  2. 5.2 Global Generic and Biosimilar Pharmaceuticals Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Generic and Biosimilar Pharmaceuticals Key Company Headquarters & Area Served
  4. 5.4 Global Generic and Biosimilar Pharmaceuticals Company, Product Type & Application
  5. 5.5 Global Generic and Biosimilar Pharmaceuticals Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Generic and Biosimilar Pharmaceuticals Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Generic and Biosimilar Pharmaceuticals Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Generic and Biosimilar Pharmaceuticals Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Johnson & Johnson
  2. 6.1.1 Johnson & Johnson Company Information
  3. 6.1.2 Johnson & Johnson Business Overview
  4. 6.1.3 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Product Portfolio
  6. 6.1.5 Johnson & Johnson Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis Generic and Biosimilar Pharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Novartis Generic and Biosimilar Pharmaceuticals Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 Merck
  14. 6.3.1 Merck Company Information
  15. 6.3.2 Merck Business Overview
  16. 6.3.3 Merck Generic and Biosimilar Pharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Merck Generic and Biosimilar Pharmaceuticals Product Portfolio
  18. 6.3.5 Merck Recent Developments
  19. 6.4 Roche
  20. 6.4.1 Roche Company Information
  21. 6.4.2 Roche Business Overview
  22. 6.4.3 Roche Generic and Biosimilar Pharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Roche Generic and Biosimilar Pharmaceuticals Product Portfolio
  24. 6.4.5 Roche Recent Developments
  25. 6.5 Eli Lilly
  26. 6.5.1 Eli Lilly Company Information
  27. 6.5.2 Eli Lilly Business Overview
  28. 6.5.3 Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Eli Lilly Generic and Biosimilar Pharmaceuticals Product Portfolio
  30. 6.5.5 Eli Lilly Recent Developments
  31. 6.6 Pfizer
  32. 6.6.1 Pfizer Company Information
  33. 6.6.2 Pfizer Business Overview
  34. 6.6.3 Pfizer Generic and Biosimilar Pharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Generic and Biosimilar Pharmaceuticals Product Portfolio
  36. 6.6.5 Pfizer Recent Developments
  37. 6.7 Amgen
  38. 6.7.1 Amgen Company Information
  39. 6.7.2 Amgen Business Overview
  40. 6.7.3 Amgen Generic and Biosimilar Pharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Amgen Generic and Biosimilar Pharmaceuticals Product Portfolio
  42. 6.7.5 Amgen Recent Developments
  43. 6.8 AbbVie
  44. 6.8.1 AbbVie Company Information
  45. 6.8.2 AbbVie Business Overview
  46. 6.8.3 AbbVie Generic and Biosimilar Pharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 AbbVie Generic and Biosimilar Pharmaceuticals Product Portfolio
  48. 6.8.5 AbbVie Recent Developments
  49. 6.9 Sanofi-Aventis
  50. 6.9.1 Sanofi-Aventis Company Information
  51. 6.9.2 Sanofi-Aventis Business Overview
  52. 6.9.3 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Product Portfolio
  54. 6.9.5 Sanofi-Aventis Recent Developments
  55. 6.10 Novo Nordisk
  56. 6.10.1 Novo Nordisk Company Information
  57. 6.10.2 Novo Nordisk Business Overview
  58. 6.10.3 Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Novo Nordisk Generic and Biosimilar Pharmaceuticals Product Portfolio
  60. 6.10.5 Novo Nordisk Recent Developments
  61. 6.11 Innovent
  62. 6.11.1 Innovent Company Information
  63. 6.11.2 Innovent Business Overview
  64. 6.11.3 Innovent Generic and Biosimilar Pharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Innovent Generic and Biosimilar Pharmaceuticals Product Portfolio
  66. 6.11.5 Innovent Recent Developments
  67. 6.12 Gelgen
  68. 6.12.1 Gelgen Company Information
  69. 6.12.2 Gelgen Business Overview
  70. 6.12.3 Gelgen Generic and Biosimilar Pharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Gelgen Generic and Biosimilar Pharmaceuticals Product Portfolio
  72. 6.12.5 Gelgen Recent Developments
  73. 6.13 Ganlee
  74. 6.13.1 Ganlee Company Information
  75. 6.13.2 Ganlee Business Overview
  76. 6.13.3 Ganlee Generic and Biosimilar Pharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Ganlee Generic and Biosimilar Pharmaceuticals Product Portfolio
  78. 6.13.5 Ganlee Recent Developments
  79. 6.14 Dong Bao
  80. 6.14.1 Dong Bao Company Information
  81. 6.14.2 Dong Bao Business Overview
  82. 6.14.3 Dong Bao Generic and Biosimilar Pharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Dong Bao Generic and Biosimilar Pharmaceuticals Product Portfolio
  84. 6.14.5 Dong Bao Recent Developments
  85. 6.15 CP Guojian
  86. 6.15.1 CP Guojian Company Information
  87. 6.15.2 CP Guojian Business Overview
  88. 6.15.3 CP Guojian Generic and Biosimilar Pharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 CP Guojian Generic and Biosimilar Pharmaceuticals Product Portfolio
  90. 6.15.5 CP Guojian Recent Developments
  91. 6.16 Changchun High Tech
  92. 6.16.1 Changchun High Tech Company Information
  93. 6.16.2 Changchun High Tech Business Overview
  94. 6.16.3 Changchun High Tech Generic and Biosimilar Pharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Changchun High Tech Generic and Biosimilar Pharmaceuticals Product Portfolio
  96. 6.16.5 Changchun High Tech Recent Developments
  97. 6.17 Biotech
  98. 6.17.1 Biotech Company Information
  99. 6.17.2 Biotech Business Overview
  100. 6.17.3 Biotech Generic and Biosimilar Pharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Biotech Generic and Biosimilar Pharmaceuticals Product Portfolio
  102. 6.17.5 Biotech Recent Developments
  103. 6.18 3sbio
  104. 6.18.1 3sbio Company Information
  105. 6.18.2 3sbio Business Overview
  106. 6.18.3 3sbio Generic and Biosimilar Pharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 3sbio Generic and Biosimilar Pharmaceuticals Product Portfolio
  108. 6.18.5 3sbio Recent Developments
7 North America
  1. 7.1 North America Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Generic and Biosimilar Pharmaceuticals Market Size by Country (2021-2026)
  3. 7.3 North America Generic and Biosimilar Pharmaceuticals Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Generic and Biosimilar Pharmaceuticals Market Size by Country (2021-2026)
  3. 8.3 Europe Generic and Biosimilar Pharmaceuticals Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Generic and Biosimilar Pharmaceuticals Market Size by Country (2021-2026)
  3. 10.3 South America Generic and Biosimilar Pharmaceuticals Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst